OBJECTIVES: Definition of the optimal cost-effective medical technology directed at the treatment / prevention from recurrent infections of lower urinary tracts (IUT) with vaginal cream Ovestin in menopausal women. METHODS: Effectiveness data was taken from the results of eight months long randomized, double-blind, placebo-controlled investigation by Raz R. and Stamm W. that was carried out at the clinic of infectious diseases of Emek central hospital, Aflua, Israel in 1993. Rate of IUT (per woman, per year) and the number of patients that had received total treatment course (%) served to be the effectiveness evaluation criteria. There were estimated the Direct medical expenses including costs of medication used for IUT prevention/treatment (based on the registered “utmost release price of manufacturing company”, extra trade prices as well as standards of IUT treatment), payments for gynecologist's or urologist's consultation, for blood count, urine test and for biochemical blood test (based on prices of out-patient medical care established at the urological and gynecological departments of I.M. Sechenov MMA clinics). RESULTS: According to Raz R. and Stamm W. data the IUT rate came to 50 and to 590 IUT cases per year per 100 women treated with either Ovestin or Placebo, respectively; treatment compliance equaled 36 / 50 (72,0%) and 24 / 43 (55,8%) in Estriol and Placebo groups, respectively. Ovestin demonstrated its superiority at every evaluated parameter. Estimation of total expenses revealed that Ovestin use contributes to saving of 673 148 RUB per 100 women in a year. CONCLUSION: Vaginal cream Ovestin proved to provide cost-effective and clinically efficacious prevention from IUT.